Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.

Automated summary

This study aimed to assess the mortality rate in patients with MOGAD and found a lower mortality rate compared to other neuroinflammatory diseases, similar to the age-adjusted mortality rates of the general population in the United States. Further studies are needed to confirm this observation.